Pfizer, Baxter, and BCBS talk Real-World Evidence. Will you be there to hear? Join our futuristic and extraordinary free (yes, FREE) 1st Virtual HEOR Conference: “Real World Evidence Virtual Summit: Practical Strategies for Addressing the Needs of Multiple Stakeholders”, December 11, 2014, 8am-5pm ET. Register today!
|IN THIS ISSUE|
|SPOTLIGHT 1 OF THE WEEK||SPOTLIGHT 2 OF THE WEEK|
|3 Ways To Get More Value From Your Global Value Dossier|
Find out how you can use a digital dossier tool to get more from your global value dossier. (Source: Andre Moa, TRiBECA KNOWLEDGE, 9/26/14).
Phase III, IV and Observational Studies – What’s On Your Checklist For Success?
In order to create Checklist for Success for Late-Phase Research, Strategic Market Insights, LLC is conducting a very short survey to gather YOUR insights on what should be on a Checklist for Success for Phase 3, 4, and Observational Studies. Results will be disseminated in an October 20th Webinar and later in a December 11, 2014 virtual meeting on Real World Evidence: Stakeholder Perspectives in HE-Xpo. (Source: Strategic Market Insight, LLC).
Watch out Gilead – France Has A New Tax In Town!
Many countries around the globe are struggling with the pricing of Gilead Sciences’ new Hepatits C drug, Sovaldi, but France has come up with an entirely new strategy: taxes! (Source: FiercePharma, 10/1/14).
How Are The 10 Most Influential Women In Healthcare Bringing Change?
MD+DI lists the top 10 women with various persuasions and backgrounds who are looking at ways to improve an outdated healthcare system and bring it into the 21st Century. Learn more about Regina Holliday and these other amazing women. (Source: MD+DI, 9/24/14).
Download CBPartners Ground-Breaking New Pricing App Today!
CBPartners is now offering a FREE app, available through iTunes, giving users mobile access to current international reference pricing rules and providing a user-friendly platform for accessing International Reference Pricing (IRP) rules-when you need them most. Check out this hot new app today and see what it can do for you! (Source: PRWeb, 10/3/14).
Why Have Papers From This Disgraced Research Group Not Been Retracted?
The New England Journal Of Medicine decided not to retract two papers reporting the results of the 1999 DECREASE 1 study and the 2009 DECREASE III study, by disgraced Dutch researcher Don Poldermans. Instead, the journal added an “Editor’s note” to the articles referring readers to a Dutch investigation into the studies. Learn more about some of the troubling discrepancies found in these reports. (Source: Larry Husten, Forbes, 9/26/14).
Call For Proposals Is Now Open For AMCP’s 27th Annual Meeting and Expo.
The event will take place April 7-10, 2015, at the San Diego Convention Center. Get your proposals in soon! (Source: AMCP, 2014).
New Draft Report on HTA Decision Models Open For Comment.
Guidance for the Conduct and Reporting of Decision and Simulation Models in the Context of Health Technology Assessment is now available for comments until October 22, 2014. (Source: AHRQ, 9/25/14).
Value-Based Reimbursement Answer Book: 97 FAQs.
This is a 60-page resource, providing a framework for healthcare’s new value proposition, with advice from thought leaders steeped in the delivery and reimbursement of value-based care. (Source: Healthcare Intelligence Network).
What Are The Greatest challenges And Opportunities For Biosimilars In Emerging Markets?
From critical components to success to which emerging markets are the most important for growth, get the information you need so your company can differentiate itself in this highly competitive market. (Source: FirstWord, 9/30/14).
HealthEconomics.Com’s Top News Of The Week!
Just in case you missed something, here’s a re-cap of last week’s news, including: The end of Market Access, Outrageous Hospital Billing, and the changes in store for NICE! Our top three most-read articles all in one place! Keeping you informed and up-to-date; it’s just what we do.
|Link of the Week||Conference of the Week||Webinar of the Week|